SG11202007319SA - Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers - Google Patents

Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers

Info

Publication number
SG11202007319SA
SG11202007319SA SG11202007319SA SG11202007319SA SG11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA
Authority
SG
Singapore
Prior art keywords
preeclampsia
prevention
methods
early prediction
associated biomarkers
Prior art date
Application number
SG11202007319SA
Other languages
English (en)
Inventor
Kevin P Rosenblatt
Thomas F Mcelrath
Brian D Brohman
Robert C Doss
Original Assignee
Nx Prenatal Inc
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nx Prenatal Inc, Brigham & Womens Hospital Inc filed Critical Nx Prenatal Inc
Publication of SG11202007319SA publication Critical patent/SG11202007319SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Artificial Intelligence (AREA)
SG11202007319SA 2018-01-31 2019-01-31 Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers SG11202007319SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624626P 2018-01-31 2018-01-31
US201862641135P 2018-03-09 2018-03-09
PCT/US2019/016188 WO2019152741A1 (en) 2018-01-31 2019-01-31 Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers

Publications (1)

Publication Number Publication Date
SG11202007319SA true SG11202007319SA (en) 2020-08-28

Family

ID=67479860

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007319SA SG11202007319SA (en) 2018-01-31 2019-01-31 Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers

Country Status (7)

Country Link
US (2) US20210050112A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746087A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021512315A (cg-RX-API-DMAC7.html)
KR (1) KR20200140796A (cg-RX-API-DMAC7.html)
CN (1) CN111918658A (cg-RX-API-DMAC7.html)
SG (1) SG11202007319SA (cg-RX-API-DMAC7.html)
WO (1) WO2019152741A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015666A1 (en) * 2020-07-13 2022-01-20 Nx Prenatal Inc. Methods of assessing risk of and treating preeclampsia and subtypes thereof
US20250102482A1 (en) * 2021-11-11 2025-03-27 Nx Prenatal Inc. Methods of preparing and analyzing samples for biomarkers associated with placenta accreta
JP2025520311A (ja) * 2022-06-21 2025-07-03 ネオプレディクス アーゲー 妊娠高血圧腎症の進展予測方法およびシステム
CN117747110B (zh) * 2023-12-26 2024-11-15 南京鼓楼医院 基于母体因素和早期孕期生物标志物的子痫前期风险预测方法及系统
DE102024100425A1 (de) * 2024-01-09 2025-07-10 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Verfahren und System zur Klassifikation eines Auftretens einer medizinischen Komplikation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
WO2014142752A1 (en) * 2013-03-12 2014-09-18 Agency For Science, Technology And Research Pre-eclampsia biomarkers
WO2015002845A1 (en) * 2013-07-01 2015-01-08 Anderson Cindy Biomarker for preeclampsia
US10656163B2 (en) * 2014-09-02 2020-05-19 Wallac Oy Method for determining risk of pre-eclampsia
RU2724013C2 (ru) * 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2017096405A1 (en) * 2015-12-04 2017-06-08 Nx Prenatal Inc. Use of circulating microparticles to stratify risk of spontaneous preterm birth

Also Published As

Publication number Publication date
US20250329468A1 (en) 2025-10-23
JP2021512315A (ja) 2021-05-13
EP3746087A4 (en) 2022-02-09
WO2019152741A1 (en) 2019-08-08
US20210050112A1 (en) 2021-02-18
CN111918658A (zh) 2020-11-10
EP3746087A1 (en) 2020-12-09
KR20200140796A (ko) 2020-12-16

Similar Documents

Publication Publication Date Title
IL274802A (en) A hybrid method of assessing and predicting athletic performance
SG11202100063YA (en) Inter prediction method and apparatus
SG11202103661XA (en) Inter prediction method and apparatus
GB201810190D0 (en) Prognostic and treatment response predictive method
IL257461B (en) A method for quantifying organs of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii and their use as biomarkers
PL3476965T3 (pl) Blacha ocynowana o wysokiej wytrzymałości i wysokim wydłużeniu oraz sposób jej podwójnej zimnej redukcji
GB2549761B (en) An automatic door installation and method of determining the presence of an obstacle
IL251204A0 (en) Biomarkers and predictive methods
SG11202003130TA (en) Prognostic and treatment response predictive method
GB2542543B (en) Stepped spiral chute assembly having friction reduction panels and method of forming same
ZA202100106B (en) Methods of treating and/or preventing actinic keratosis
ZA201802481B (en) Novel biomarkers and methods of treating cancer
IL263025A (en) A method and system for predicting the prognosis for kidney disease
EP3494232A4 (en) BIOMARKERS FOR PREDICTING PREMATURE DELIVERY IN A GRAVID FEMALE EXPOSED TO PROGESTOGENS
EP3365467A4 (en) SYSTEM AND METHOD FOR DIAGNOSING ENDOTHELIAL DYSFUNCTION USING CIRCULATING MIARN AS BIOMARKERS
GB2573182B (en) Steel profile and method of processing steel
GB2527541B (en) An access cover assembly and methods of its installation and manufacture
PT3177922T (pt) Procedimento para o rastreio da drepanocitose
SG11201706249RA (en) Biomarkers for diagnosis and prognosis of corneal ectatic disorders
IL273584A (en) Methods to reverse the normal aging date and extend life span
SG11202012687SA (en) Method for detection and quantification of genetic alterations
PL3837821T3 (pl) Ocena stanu rzeczywistych obiektów
HK40042292A (en) Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers
GB201617722D0 (en) Method for determining prognosis of cancer
GB201910133D0 (en) Method of prognosing and diagnosing preeclampsia